Investerenkanjeleren schreef op 11 mei 2021 13:11:
[...]
Het onderstaande komt uit de earningscall van afgelopen vrijdag:
Onno van de Stolpe -- Chief Executive Officer and Member of Board of Directors
'Bart, do you want me to start on Toledo?'
Bart Filius -- Chief Financial Officer and Member of Board of Directors
'Yes, Piet go ahead.'
Piet Wigerinck -- Chief Scientific Officer and Member of Management Board
'Yes. Okay. On the create proof of concept.
So we, first of all, very pleased with the progress we made. So three of those studies are fully recruited. One is completed. And so we are pleased that over summer, we can present to you all of the data. As I said before, as well these trials are designed while small to generate clinical data that should allow us to estimate the magnitude of the clinical effect we can get with this compound and with this mechanism of action in these patients. So if you would see a biomarker senior only, we would be disappointed here. So we really hope to see clinical effects in each of the studies. And then based on those determined what is the disease that is the most appropriate to take this program forward in.'